| Literature DB >> 33121465 |
M A Alazrag1, A M Abu-Seida2, K M El-Batouty1, S H El Ashry1.
Abstract
BACKGROUND: This study evaluated the marginal adaptation, solubility and biocompatibility of TheraCal LC compared with mineral trioxide aggregate (MTA-Angelus) and Biodentine when used as a furcation perforation repair material.Entities:
Keywords: Biocompatibility; Biodentine; Furcal perforation; MTA; Marginal adaptation; TheraCal LC
Mesh:
Substances:
Year: 2020 PMID: 33121465 PMCID: PMC7599098 DOI: 10.1186/s12903-020-01289-y
Source DB: PubMed Journal: BMC Oral Health ISSN: 1472-6831 Impact factor: 2.757
Frequency distribution of radiolucency (%) for all subgroups after one month and three months groups
| Subgroups | 1 month group | 3 months group | ||
|---|---|---|---|---|
| Presence | Absence | Presence | Absence | |
| MTA | 10 | 90 | 20% | 80 |
| Biodentine | 20 | 80 | 30% | 70 |
| TheraCal LC | 40 | 60 | 90% | 10 |
| Control | 100 | 0 | 100 | 0 |
| Chi value | 199 | 208 | ||
| < 0.0001* | < 0.0001* | |||
*P < 0.05
Fig. 2a A representative periapical radiograph of the MTA subgroup immediately post perforation repair. b Periapical radiograph of the MTA subgroup showing absence of furcal radiolucency and bony defect after 3 months of evaluation. c A representative periapical radiograph of the Biodentine subgroup immediately post perforation repair. d A periapical radiograph of the Biodentine subgroup showing absence of furcal radiolucency and bony defect after 3 months of evaluation
Fig. 3a A representative periapical radiograph of the TheraCal LC subgroup immediately post perforation repair. b A periapical radiograph of the TheraCal LC subgroup showing presence of furcal radiolucency and bony defect after 3 months of evaluation. c A representative periapical radiograph of the positive control subgroup immediately post perforation. d A periapical radiograph of the positive control subgroup showing presence of furcal radiolucency and bony defect after one month of evaluation
Frequency distribution of inflammatory scores percentage for all subgroups after one month and three months groups
| Subgroups | Score 0 | Score 1 | Score 2 | Score 3 | ||||
|---|---|---|---|---|---|---|---|---|
| 1 month | 3 months | 1 month | 3 months | 1 month | 3 months | 1 month | 3 months | |
| MTA | 0 | 0 | 70% | 80 | 30% | 20% | 0 | 0 |
| Biodentine | 0 | 0 | 60% | 70 | 40% | 30% | 0 | 0 |
| TheraCal LC | 0 | 0 | 50% | 10 | 50% | 50% | 0 | 40% |
| Control | 0 | 0 | 0 | 0 | 60% | 60% | 40% | 40% |
| Chi value | 195.6 | 230 | 195.6 | 230 | 195.6 | 230 | 195.6 | 230 |
| < 0.0001* | < 0.0001* | < 0.0001* | < 0.0001* | < 0.0001* | < 0.0001* | < 0.0001* | < 0.0001* | |
*P < 0.05
Fig. 4a A representative photomicrograph of the MTA-Angelus subgroup showing a score 1 inflammatory cell count after 1 month of evaluation (H&E, × 400). b A representative photomicrograph of the Biodentine subgroup showing a score 2 inflammatory cell count after 1 month of evaluation (H&E, × 400). c A representative photomicrograph of the TheraCal LC subgroup showing a score 3 inflammatory cell count after three months of evaluation (H&E, × 400). d A representative photomicrograph of the positive control subgroup showing a score 3 inflammatory cell count after three months of evaluation (H&E, × 400)
Comparison of frequency distribution of inflammatory scores percentage for each subgroup between one month and three months groups
| Scores | MTA | Biodentine | TheraCal LC | Control | ||||
|---|---|---|---|---|---|---|---|---|
| 1 month | 3 months | 1 month | 3 months | 1 month | 3 months | 1 month | 3 months | |
| Score 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Score 1 | 70% | 80% | 60% | 70% | 50% | 10% | 0 | 0 |
| Score 2 | 30% | 20% | 40% | 30% | 50% | 50% | 60% | 60% |
| Score 3 | 0 | 0 | 0 | 0 | 0 | 40% | 40% | 40% |
| Chi value | 2.16 | 1.8 | 66 | 0 | ||||
| 0.1416 ns | 0.186 ns | 0.0001* | 1 ns | |||||